Última actualización 11 de julio de 2026
Key finding
BMI decreased significantly in the liraglutide group compared to the control group.
This study investigated the effects of liraglutide combined with CPAP on patients with Type 2 diabetes and severe obstructive sleep apnea, finding significant improvements in several health metrics.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated the effects of liraglutide combined with CPAP on patients with Type 2 diabetes and severe obstructive sleep apnea, finding significant improvements in several health metrics.
These findings are clinically significant as they suggest that liraglutide can enhance the effectiveness of CPAP therapy in improving health outcomes for patients with Type 2 diabetes and severe obstructive sleep apnea, potentially leading to better management of these interconnected conditions.
The study's sample size and demographic characteristics may limit generalizability. Potential confounding factors were not fully controlled for. The long-term effects of liraglutide in this population remain unclear.
Published in
Publication details and source links for this paper.
Wenlong J, Weiguo L, Jing C, Wen L, Fangzhou C. Liraglutide Combined with CPAP Improves Outcomes in Patients with Type 2 Diabetes and Severe Obstructive Sleep Apnea. Sleep & Breathing = Schlaf & Atmung. 2022;27(5):1687-1694. doi:10.1007/s11325-022-02768-y
Liraglutide treatment resulted in a significant decrease in BMI by 2.1 kg/m² (P < 0.05).
The AHI decreased by 4.9 events/hour in the liraglutide group (P < 0.05).
Mean systolic blood pressure decreased by 5.6 mmHg in the liraglutide group (P < 0.05).
Minimum oxygen saturation increased by 3.1% in the liraglutide group (P < 0.05).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Liraglutide and Apnea Hypopnea Index (AHI), BMI, Gastrointestinal disorders incidence, and 2 more.
This study contributes evidence to
Primary intervention
Liraglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
5
Evidence pairs
163
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Seguir evidencia
Relación de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
Liraglutide → Apnea Hypopnea Index (AHI)
Liraglutide → Apnea Hypopnea Index (AHI)
Liraglutide → Gastrointestinal disorders incidence
Liraglutide → Gastrointestinal disorders incidence
Liraglutide → Minimum Oxygen Saturation Improvement
Liraglutide → Minimum Oxygen Saturation Improvement
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Mass Index, GLP-1 Receptor Agonists and Gastrointestinal Adverse Events.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Mass Index
Measures Body Mass Index as a key outcome.
All studies measuring Gastrointestinal Adverse Events
Measures Gastrointestinal Adverse Events as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
Jump to pre-filtered views in the evidence archive.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may worsen Gastrointestinal Adverse Events or be associated with harm.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Gastrointestinal disorders incidence
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 5 supporting studies and existing graph evidence signals.
Limitations
GLP-1 Receptor Agonists may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
Liraglutide appears to improve Apnea Hypopnea Index (AHI).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Apnea Hypopnea Index (AHI)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.